AI and early digital twin models can help forecast trial performance, refine site feasibility, and anticipate operational needs before enrollment begins.
- A Framework For Diagnosing Clinical Research Technology Maturity
- Clinical Trial Sites Don't Need More Tech, They Need Fewer Silos
- A Biostatistician's Caution Around Digital Twins In Trials
- Who Owns Data Quality? The Authority Gap Slowing Trials
- Clinical Research Isn't Even A Recognized Job. That's A Problem.
- What Will Life Science Orgs Do When The AI Bill Comes Through?
- Clinical Trial Standards — What They Are And Why They're Indispensable
- The Data Was Already There: RWE's Real Bottleneck Is People
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Why Legacy RTSM Systems Create Risk in Biosimilar Trials
Learn how real-time visibility, adaptive supply planning, and proactive risk management can reduce waste and improve study execution.
-
You Don't Have To Digitize Everything, You Just Have To Start
Feeling left behind by the sudden digitization of clinical trials? Decentralized clinical trials can be adapted to best serve the patient population, condition, or therapy you’re investigating.
-
How A Remote ePRO Solution Helped Reduce Patient Burden
Discover how transitioning multiple studies from on-site to at-home assessments improved patient retention and recruitment for a global neurology program.
-
Key Takeaways From The Recent FDA DCT Draft Guidance
Get an overview of draft perspectives and key points to reinforce decentralized clinical trial training, oversight, and risk assessment to guarantee a study's integrity, patient safety, and success.
-
Connected Data For Mission-Critical, Time-Sensitive Moments In A Clinical Trial
Embrace the power of a unified eCOA and IRT platform to drive smarter decisions, ensure data accuracy, and boost efficiency across your studies.
-
Real-World Data Capture With EDC
This case study explores how a Ph.D. candidate partnered with Castor to develop software that seamlessly moves RWD between hospital systems and Castor’s EDC.
-
The Strategic Role Of KOLs In Rare Disease Drug Development
Engaging key Opinion Leaders (KOL) is crucial for accelerating rare disease research breakthroughs. However, identifying the right experts is challenging due to fragmented data and evolving expertise.
-
Enhancing Participant Payments: A New Approach
Managing participant payments in clinical trials is a multifaceted challenge impacting participants, sites, and sponsors alike. Delve into the intricacies and numerous hurdles faced in this process.
-
eCOA Evolution: Have We Overcomplicated It?
eCOA has evolved from simple data collection to complex patient engagement platforms, raising concerns about added complexity. Explore innovative tools aimed at simplifying this complexity.
-
Paper COAs In 2026? It's Not "Cheaper," It's Riskier
Paper-based assessments add operational and regulatory risk — from poor data quality to delayed insights — quietly threatening timelines, compliance, and trial confidence.
- How AI Is Used To Predict Trial Performance Before Enrollment
- Two Planning Mistakes That Quietly Sink Clinical Programs
- A Framework For Diagnosing Clinical Research Technology Maturity
- Clinical Trial Sites Don't Need More Tech, They Need Fewer Silos
- A Biostatistician's Caution Around Digital Twins In Trials
RECENT NEWSLETTERS
- 09.24.26 -- AI, Wearables, And CRA Workflows Are Exposing Trial Gaps
- 09.17.26 -- AI, Wearables, And eTMF Are Exposing Trial Data Gaps
- 09.10.26 -- AI, Trial Costs, And RTSM Are Reshaping Clinical Operations
- 09.05.26 -- Best Of August: AI, FDA RWE, And Trial Data Risks
- 09.03.26 -- AI, APIs, and eConsent Are Exposing Trial Workflow Gaps